ArticleFrontiers in immunology2023
ILC2 require cell-intrinsic ST2 signals to promote type 2 immune responses.
Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Interleukin-33 and its receptor: multifaceted roles and emerging therapeutic potential.Nature reviews. Immunology · 2026Review
- Blimp-1 integrates alarmin signals in ILC2s and drives proinflammatory functions required for type 2 immunity.The Journal of experimental medicine · 2026Article
- How to Employ Trained Immunity and Trained Immunity-Based Vaccines to Inhibit Allergic Inflammation.Vaccines · 2026Review
- Neuro-immune Crosstalk in Atopic Dermatitis: A Multiaxial Regulatory Network and Novel Therapeutic Perspectives.Clinical reviews in allergy & immunology · 2026Review
- Distinguishing Features of ILC2s During Type 2 Immune Responses.European journal of immunology · 2026Review
- Divergent aging of nulliparous and parous mammary glands reveals IL33+ hybrid epithelial cells.Nature communications · 2026Article
- New Perspectives on Classical Alarmin Responses to Intestinal Helminth Infection.Parasite immunology · 2025Review
- Skin damage signals mediate allergic sensitization to spatially unlinked antigen.Science immunology · 2025Article
- Established and Emerging Biological Therapies for the Treatment of Comorbid Asthma and Chronic Obstructive Pulmonary Disease.Journal of inflammation research · 2025Review
- Immunometabolic analysis of primary murine group 2 innate lymphoid cells: a robust step-by-step approach.Frontiers in immunology · 2025Article
- Group 2 innate lymphoid cells are a non-redundant source of interleukin-5 required for development and function of murine B1 cells.Nature communications · 2024Article
- Unveiling the Neuron-mediated Group 2 Innate Lymphoid Cell Activation in Human Asthma.American journal of respiratory and critical care medicine · 2024Article
- Immune Response Dynamics and Biomarkers in COVID-19 Patients.International journal of molecular sciences · 2024Article
- TL1A is an epithelial alarmin that cooperates with IL-33 for initiation of allergic airway inflammation.The Journal of experimental medicine · 2024Article
- Cooperation of ILC2s and TNature reviews. Immunology · 2024Review
- Analysis of lipid uptake, storage, and fatty acid oxidation by group 2 innate lymphoid cells.Frontiers in immunology · 2024Article
- Transcriptional profiling identifies IL-33-expressing intestinal stromal cells as a signaling hub poised to interact with enteric neurons.Frontiers in cell and developmental biology · 2024Article
- The epithelium takes the stage in asthma and inflammatory bowel diseases.Frontiers in cell and developmental biology · 2024Review
- Possible connection between intestinal tuft cells, ILC2s and obesity.Frontiers in immunology · 2023Review
- Type 2 innate lymphoid cells are not involved in mouse bladder tumor development.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
The initiation of type 2 immune responses at mucosal barriers is regulated by rapidly secreted cytokines called alarmins. The alarmins IL-33, IL-25 and TSLP are mainly secreted by stromal and epithelial cells in tissues and were linked to chronic inflammatory diseases, such as allergic lung inflammation, or to resistance against worm infections. Receptors for alarmins are expressed by a variety of immune cells, including group 2 innate lymphoid cells (ILC2s), an early source of the type 2 cytokines, such as IL-5 and IL-13, which have been linked to atopic diseases and anti-worm immunity as well. However, the precise contribution of the IL-33 receptor signals for ILC2 activation still needs to be completed due to limitations in targeting genes in ILC2. Using the newly established
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.